Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

OncoCyte Corporation (OCX)

2.51   0.07 (2.87%) 02-14 16:00
Open: 2.49 Pre. Close: 2.44
High: 2.6 Low: 2.42
Volume: 190,522 Market Cap: 157M
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.601 - 2.617 2.617 - 2.632
Low: 2.385 - 2.402 2.402 - 2.419
Close: 2.482 - 2.509 2.509 - 2.534

Technical analysis

as of: 2020-02-14 4:31:18 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.29     One year: 3.61
Support: Support1: 2.37    Support2: 1.97
Resistance: Resistance1: 2.81    Resistance2: 3.09
Pivot: 2.60
Moving Average: MA(5): 2.51     MA(20): 2.67
MA(100): 2.08     MA(250): 2.74
MACD: MACD(12,26):     Signal(9): 0.05
Stochastic oscillator: %K(14,3): 15.15     %D(3): 10.44
RSI: RSI(14): 47.19
52-week: High: 5.60  Low: 1.50  Change(%): -34.1
Average Vol(K): 3-Month: 31462  10-Days: 16878

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
OCX has closed above bottom band by 23.7%. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2020-01-23
OncoCyte Enters Into The Cancer Immunotherapy Field With The Acquisition Of Insight Genetics
OncoCyte surprises us again with an acquisition, this time it has been Insight Genetics (IG). This acquisition enables OCX to enter into the oncological immunot

2020-01-13
5 Stocks To Watch For January 13, 2020
Some of the stocks that may grab investor focus today are: OncoCyte Corp (NYSE: OCX) announced plans to acquire Insight Genetics for $12 million. OncoCyte …

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE American
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 60.56
Shares Float (M) 19.07
% Held by Insiders 24.80
% Held by Institutions 40.09
Shares Short (K) 1250
Shares Short P. Month (K)

Stock Financials

EPS -0.397
Book Value (p.s.) 0.560
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -48.5
Return on Equity (ttm) -102.9
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.286
Qtrly Earnings Growth
Operating Cash Flow (M) -16.86
Levered Free Cash Flow (M) -9.12

Stock Valuations

P/E -6.32
P/E Growth Ratio 0.03
P/BV 4.48
P/S
P/CF -9.02

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.